This is the conclusion of an American study published Thursday, May 7 in the leading scientific journal New England Journal of Medicine.
Funded by the American Institutes of Health (NIH), it was conducted on patients admitted to the emergency departments of New York-Presbyterian Hospital and Columbia University Irving Medical Center.
No improvement or deterioration
811 patients received two doses of 600 mg of hydroxychloroquine on the first day, then 400 mg daily for four days.
565 patients did not receive the medicine.
As a result, administration of hydroxychloroquine did not significantly improve or worsen the condition of critically ill Covid-19 patients compared to patients who received nothing.
>> READ ALSO. Hydroxychloroquine, remdesivir, kaletra … These drugs at the center of the fight against the coronavirus
Be careful
Scientists remain cautious: this study “should not be used to spread” the potential benefits or risks of treatment with hydroxychloroquine.
“However, our results do not support [son] use at the moment, apart from randomized clinical trials [répartissant les patients par tirage au sort, Ndlr] in order to demonstrate its effectiveness. “
